Cefotiam Hydrochloride
The hydrochloride salt form of cefotiam is used for parenteral administration in treating susceptible bacterial infections. It retains the second-generation cephalosporin spectrum without the coagulation-interfering side chain of some related antibiotics. It remains in use mainly in Asian and European countries.
Moleküler Ağırlık
598,6000 g/mol
TPSA
251,00 Ų
Etki Mekanizması
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
2D Yapı
Cite this structure
Embed this structure
SMILES
CN(C)CCn1nnnc1SCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)Cc3csc(N)n3)[C@H]2SC1.Cl.Cl
InChI
InChI=1S/C18H23N9O4S3.2ClH/c1-25(2)3-4-26-18(22-23-24-26)34-7-9-6-32-15-12(14(29)27(15)13(9)16(30)31)21-11(28)5-10-8-33-17(19)20-10;;/h8,12,15H,3-7H2,1-2H3,(H2,19,20)(H,21,28)(H,30,31);2*1H/t12-,15-;;/m1../s1
Molecular Formula
C18H25Cl2N9O4S3
HBD / HBA
5 / 13
Döndürülebilir Bağlar
10
Ağır Atomlar
36
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
The hydrochloride salt form of cefotiam is used for parenteral administration in treating susceptible bacterial infections. It retains the second-generation cephalosporin spectrum without the coagulation-interfering side chain of some related antibiotics. It remains in use mainly in Asian and European countries.
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Yes, Cefotiam Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4303232. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 47896. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="cefotiam-hydrochloride"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/cefotiam-hydrochloride/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/cefotiam-hydrochloride/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/cefotiam-hydrochloride/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="cefotiam-hydrochloride"></drugfyi-drug>